HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BP-5-087

a STAT3 inhibitor; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ahmad, Shazia: 1 article (03/2015)
2.	Anderson, David J: 1 article (03/2015)
3.	Arpin, Carolynn C: 1 article (03/2015)
4.	Baron, Riccardo: 1 article (03/2015)
5.	Deininger, Michael W: 1 article (03/2015)
6.	Eiring, Anna M: 1 article (03/2015)
7.	Engar, Alexander J: 1 article (03/2015)
8.	Gunning, Patrick T: 1 article (03/2015)
9.	Heaton, William L: 1 article (03/2015)
10.	Khorashad, Jamshid S: 1 article (03/2015)

Related Diseases

1.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 03/01/2015 - "In primary cells from chronic myeloid leukemia (CML) patients with BCR-ABL1 kinase-independent TKI resistance, BP-5-087 (1.0 μM) restored TKI sensitivity to therapy-resistant CML progenitor cells, including leukemic stem cells. "
2.	Neoplasms (Cancer) 03/01/2015 - "Our findings implicate STAT3 as a critical signaling node in BCR-ABL1 kinase-independent TKI resistance, and suggest that BP-5-087 has clinical utility for treating malignancies characterized by STAT3 activation. "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)

Related Therapies and Procedures

1.	Therapeutics